Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)

Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)

Approximately a third of patients diagnosed with kidney cancer in the United States present with advanced disease and those who present with distant metastases historically had dismal 5-year relative survival. However, over the last several years, advancements have led to improved life expectancy an...

Full description

Bibliographic Details
Main Authors:	Eun-mi Yu, Mythri Mudireddy, Ishan Patel, Jeanny B. Aragon-Ching
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Uro
Subjects:	metastatic renal cell carcinoma checkpoint inhibitors VEGF inhibitors nivolumab ipilimumab
Online Access:	https://www.mdpi.com/2673-4397/3/2/14

Similar Items

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
by: Wolfram Samlowski, et al.
Published: (2021-11-01)

Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience
by: Ming-Wei Kao, et al.
Published: (2023-04-01)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
by: Gabriele Madonna, et al.
Published: (2021-08-01)

Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC)
by: Amr Mohamed, et al.
Published: (2022-05-01)

Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
by: Yusuke Kunimatsu, et al.
Published: (2023-04-01)

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
by: Vincenzo Quagliariello, et al.
Published: (2020-10-01)

Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature
by: Johann Stuby, et al.
Published: (2020-11-01)

Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy
by: Saskia Bolz, et al.
Published: (2021-03-01)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
by: Karlsson AK, et al.
Published: (2017-08-01)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
by: Jan-Michael Werner, et al.
Published: (2019-02-01)

News in immunotherapy for metastatic melanoma: prolgolimab in clinical practice (authors' experience)
by: Liana V. Oganesyan, et al.
Published: (2023-12-01)

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
by: Marc-Oliver Grimm, et al.
Published: (2021-11-01)

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
by: Taylor E. Woo, et al.
Published: (2023-09-01)

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
by: Moshe C. Ornstein, et al.
Published: (2019-05-01)

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
by: S. Morteza Seyed Jafari, et al.
Published: (2020-10-01)

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
by: Omid Kooshkaki, et al.
Published: (2020-06-01)

Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature
by: Lisa M. Cordes, et al.
Published: (2020-01-01)

Associated Myocarditis: A Predictive Factor for Response?
by: Walid Shalata, et al.
Published: (2020-05-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Pyoderma Gangrenosum Following Initiation of Immune Checkpoint Inhibitor Therapy
by: Macartney E Welborn, et al.
Published: (2018-10-01)

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
by: Camilo Jimenez, et al.
Published: (2022-01-01)

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
by: Marieke J. Krimphove, et al.
Published: (2019-11-01)

Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report
by: Carolin Krekeler, et al.
Published: (2023-07-01)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
by: Bianca Gautron Moura, et al.
Published: (2022-12-01)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
by: W. J. Mullally, et al.
Published: (2022-04-01)

Prospects of application of inhibitors of PD-1/PD-L1 checkpoints in malignant tumors of the stomach and esophagogastric junction
by: D. D. Sakaeva, et al.
Published: (2020-12-01)

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
by: Houssein Safa, et al.
Published: (2019-11-01)

Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report
by: Adeel Masood, et al.
Published: (2021-12-01)

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
by: Yasuyuki Miyauchi, et al.
Published: (2021-10-01)

Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
by: Pouyan N. Changizzadeh, et al.
Published: (2017-12-01)

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
by: Tony Zibo Zhuang, et al.
Published: (2022-06-01)

T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
by: Takuro Kobayashi, et al.
Published: (2023-11-01)

Pigmentary retinopathy associated with immune therapy for advanced cutaneous melanoma
by: Andrew C. Lin, et al.
Published: (2023-06-01)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
by: Xin Zhao, et al.
Published: (2022-06-01)

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
by: Sergio Di Molfetta, et al.
Published: (2021-04-01)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021-01-01)

Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma
by: Maria Paparoupa, et al.
Published: (2020-10-01)

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
by: Yuanquan Yang, et al.
Published: (2022-04-01)

Stage 4 Cytokine Release Syndrome Caused by the First Dose of Nivolumab and Ipilimumab Combination Therapy in a Patient with Metastatic Melanoma Successfully Treated with Methylprednisolone, Tocilizumab, and Etanercept
by: Sasmith R. Menakuru, et al.
Published: (2022-06-01)